Adaptive Biotechnologies (ADPT)
NASDAQ:ADPT
Want to see ADPT full AI Analyst Report?
Top Page
Adaptive Biotechnologies
(NASDAQ:ADPT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$15.00
▲(3.66% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by still-weak financial fundamentals (ongoing losses and negative free cash flow despite improving trends) and a technically weak price setup (below key moving averages). These are partially offset by a strong earnings-call outlook centered on accelerating MRD momentum, raised guidance, margin expansion, and a stated 2026 path to positive adjusted EBITDA and free cash flow, while valuation remains difficult to assess favorably due to a negative P/E and no dividend data.
Positive Factors
MRD Clinical Momentum and Adoption
Sustained double-digit MRD growth and an upgraded full-year MRD guide reflect durable clinical adoption of clonoSEQ, expanding clinician ordering and test volumes. Broader clinician penetration and volume scale support recurring revenue, pricing leverage, and multi-year demand visibility.
Negative Factors
Ongoing Net Losses and Negative Free Cash Flow
Despite improving trends, persistent negative operating and free cash flow constrain financial flexibility and force reliance on existing cash or capital markets. Continued losses increase sensitivity to adverse reimbursement or execution hiccups and lengthen the timeline to self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
MRD Clinical Momentum and Adoption
Sustained double-digit MRD growth and an upgraded full-year MRD guide reflect durable clinical adoption of clonoSEQ, expanding clinician ordering and test volumes. Broader clinician penetration and volume scale support recurring revenue, pricing leverage, and multi-year demand visibility.
Read all positive factors
Adaptive Biotechnologies Key Performance Indicators (KPIs)
Any
Adjusted EBITDA by Segment
Reveals profitability across different business units, highlighting which segments are driving earnings and operational efficiency.
Reveals profitability across different business units, highlighting which segments are driving earnings and operational efficiency.
Data provided by:
The Fly
The FlyAdaptive Biotechnologies (ADPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.42B
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth55.87%
EPS Growth66.29%
CountryUS
Employees619
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding160,044,390
10 Day Avg. Volume1,618,609
30 Day Avg. Volume1,626,836
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)11.26
Price to Sales (P/S)8.90
P/FCF Ratio-50.34
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue8.65
Enterprise Value/Gross Profit11.49
Enterprise Value/Ebitda-115.99
Forecast
1Y Price Target
$20.17Price Target Upside39.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$286.19M
Adaptive Biotechnologies Business Overview & Revenue Model
Company Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to ...
How the Company Makes Money
Adaptive Biotechnologies primarily generates revenue from two main sources: (1) diagnostic and clinical testing, and (2) research and development (R&D) services/partnerships leveraging its immune repertoire sequencing platform and resulting datase...
Adaptive Biotechnologies Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call portrays a company with strong, broad-based MRD momentum: double-digit revenue growth, volume records, margin expansion, a raised MRD revenue guide, growing backlog, and improving MRD profitability. Challenges are concentrated in the immune medicine business (declining revenue and losses), company-level net loss and elevated operating expenses, milestone lumpiness, and reimbursement/regulatory uncertainty. Taken together the positives—notably durable clinical adoption, pricing gains, margin improvement, a large and growing backlog, and a solid cash position—outweigh the negatives, which are largely isolated or acknowledged with mitigations in progress.Positive Updates
Strong Top-Line Growth
Total revenue of $70.9M, up 45% year over year, driven primarily by MRD which accounted for ~95% of revenue.
Negative Updates
Immune Medicine Revenue and Profitability Pressure
Immune medicine revenue was $3.8M, down 26% YoY, and segment adjusted EBITDA loss of $10.4M, reflecting timing of samples/processing and continued investment needs.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Total revenue of $70.9M, up 45% year over year, driven primarily by MRD which accounted for ~95% of revenue.
Read all positive updates
Company Guidance
Management raised full-year MRD revenue guidance to $260–$270 million (up from $255–$265M), which includes $9 million of MRD milestone revenue recognized in Q1 (and no additional milestones expected), with the midpoint implying ~25% YoY growth (or ~33% ex-milestones) and MRD seasonality of ~45% H1 / 55% H2; they now expect MRD volumes to grow at least 35% in 2026 (Q1 clonoSEQ volume ~32,600, +9% sequential) and continue to target a U.S. ASP of ~$1,400 per test (Q1 ASP $1,360, +11% YoY). Q1 sequencing gross margin was 70% (up 8 percentage points YoY) and management is targeting >70% (with a ~75% “north star”); backlog was ~$254M (+24% YoY), total revenue in Q1 was $70.9M (+45% YoY) with MRD representing ~95%, cash at quarter end was ~$222M, full-year total operating expense guidance is $350–$360M (≈75% allocated to MRD, ~20% to immune medicine), expected cash burn $15–$20M, and the company is reiterating its goal of positive adjusted EBITDA and positive free cash flow for 2026.Adaptive Biotechnologies Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 295.41M | 276.98M | 178.96M | 170.28M | 185.31M | 154.34M |
| Gross Profit | 222.32M | 205.62M | 106.88M | 94.72M | 127.40M | 105.04M |
| EBITDA | -22.03M | -29.85M | -128.76M | -189.27M | -175.21M | -193.34M |
| Net Income | -49.68M | -59.50M | -159.49M | -225.25M | -200.19M | -207.28M |
Balance Sheet | ||||||
| Total Assets | 505.94M | 512.74M | 539.38M | 661.13M | 856.62M | 923.34M |
| Cash, Cash Equivalents and Short-Term Investments | 218.33M | 226.98M | 222.29M | 346.40M | 498.20M | 353.06M |
| Total Debt | 208.18M | 280.58M | 89.39M | 98.77M | 108.00M | 111.74M |
| Total Liabilities | 281.70M | 287.74M | 336.89M | 352.86M | 392.52M | 319.24M |
| Stockholders Equity | 216.34M | 218.79M | 202.71M | 308.40M | 464.17M | 603.99M |
Cash Flow | ||||||
| Free Cash Flow | -29.54M | -48.95M | -98.88M | -167.02M | -200.29M | -254.47M |
| Operating Cash Flow | -27.04M | -45.99M | -95.21M | -156.32M | -183.94M | -192.73M |
| Investing Cash Flow | 21.52M | 37.95M | 77.79M | 129.65M | 2.90M | 181.21M |
| Financing Cash Flow | 32.45M | 30.40M | 241.00K | 2.25M | 132.26M | 27.15M |
Adaptive Biotechnologies Technical Analysis
Positive
14.47
Price Trends
13.99
Positive
15.11
Positive
15.19
Negative
Market Momentum
0.26
Negative
60.80
Neutral
85.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADPT, the sentiment is Positive. The current price of 14.47 is above the 20-day moving average (MA) of 13.95, above the 50-day MA of 13.99, and below the 200-day MA of 15.19, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 60.80 is Neutral, neither overbought nor oversold. The STOCH value of 85.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADPT.
Adaptive Biotechnologies Risk Analysis
Adaptive Biotechnologies disclosed 70 risk factors in its most recent earnings report. Adaptive Biotechnologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adaptive Biotechnologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.79B | 12.27 | 17.19% | ― | 20.71% | -5.53% | |
64 Neutral | $2.60B | -1,131.94 | -1.41% | ― | 95.29% | 98.21% | |
62 Neutral | $6.35B | -12.46 | -68.16% | ― | ― | -1.22% | |
61 Neutral | $1.50B | -79.71 | -4.83% | ― | 23.64% | -29.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.92B | -3.41 | -54.32% | ― | 11.07% | 32.35% | |
49 Neutral | $2.42B | -47.40 | -24.26% | ― | 55.87% | 66.29% |
* Healthcare Sector Average
ADPT
Adaptive Biotechnologies
15.14
5.20
52.31%
IMVT
Immunovant
30.92
15.48
100.26%
ARQT
Arcutis Biotherapeutics
20.79
7.52
56.67%
HRMY
Harmony Biosciences Holdings
30.91
-4.40
-12.46%
IMCR
Immunocore Holdings
29.56
-9.08
-23.50%
RXRX
Recursion Pharmaceuticals
3.61
-0.78
-17.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.